Experts discuss the brain circuits involved in schizophrenia, the current medications, and new agents in phase 3 trials that do not directly block postsynaptic D2 receptors. Phase 2 data on one of these agents, the TAAR1 agonist ulotaront, are summarized.
Save
Cite